December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

7.000 -0.060 (-0.85%)
Streaming Delayed Price Updated: 11:04 AM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
DiaMedica Posts Narrower Loss in Q2
Via The Motley Fool
Topics Intellectual Property
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Reports Q2 2025 Earnings: Narrower Loss and Promising Clinical Updates Drive Stock Surge
DiaMedica Therapeutics reports Q2 2025 results with a narrower-than-expected loss, positive clinical updates, and strong cash position. Stock surges 19% post-earnings. 
Via Chartmill
Exploring DiaMedica Therapeutics's Earnings Expectations
 
Via Benzinga
Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings
 
Via Benzinga
Earnings Scheduled For November 13, 2024
 
Via Benzinga
Preview: DiaMedica Therapeutics's Earnings
 
Via Benzinga
Recap: DiaMedica Therapeutics Q4 Earnings
 
Via Benzinga
Earnings Outlook For DiaMedica Therapeutics
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Earnings Scheduled For March 17, 2025
 
Via Benzinga
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Earnings Preview: DiaMedica Therapeutics
 
Via Benzinga
DiaMedica Therapeutics's Earnings Outlook
 
Via Benzinga
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
 
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a  
Via Benzinga
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday. 
Via Benzinga
DiaMedica Therapeutics: Q2 Earnings Insights
  DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:30 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
DiaMedica Therapeutics Earnings Preview
  DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.